Bavarian Nordic on FDA special status: A huge validation
On Monday, the FDA awarded Danish biotech firm Bavarian Nordic a special regulatory status, which could cut down case processing of the firm’s RSV vaccine candidate. While a phase III trial is slated to begin soon, Bavarian still lags behind in the race to reach the potential billion-dollar RSV market. Still, there’s enough money to go around, says VP of communications, Rolf Sass Sørensen.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
It’s a feather in Bavarian Nordic’s cap to have been granted the especially sought-after special regulatory status for the company’s RSV vaccine candidate, dubbed MVA-BN RSV, from the US Food and Drug Administration (FDA) on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic finds buyers for accelerated share offering
For subscribers
Bavarian Nordic receives special designation from FDA
For subscribers
